Patented Pharmaceutical Reconstitutable Sustained Release Suspension

At the present time reconstitutable suspensions are obtainable in a market. Oral liquor suspensions are majorly designed for the patients with difficulty in swallowing. Reconstitutable suspensions necessitate water to prior for mixing. Sustained release (SR) suspensions aimed at controlling the rate of release by maintaining desire drug levels in the blood for long duration of time. An oral suspension could be the most excellent fitting dosage form intended for geriatric and pediatric patients. They comprise improvement of the rate and extent of drug absorption, higher patient compliance, reduction of side effects and taste masking of bitter drug.Reconstitutable SR suspensions are prepared by numerous novel approaches to design and development of variety of drugs. They are prepared by using a variety of polymer like Cellulose acetate, EC, HPMC phthalate, Eudragit, Xanthan gum etc. for enteric coating purpose, which are give controlled drug delivery from the granules. SR suspension developed into the research characterized by Scanning electron microscopy (SEM), particle size analysis, drug entrapment efficiency, and In-vitro Drug Release. SR suspension will be benefited to avoid fluctuations in blood drug plasma concentration and gives its action for an entire period of time.

[1]  S. H. Jaber,et al.  Formulation of Azithromycin Suspension as an Oral Dosage Form , 2017, Iraqi Journal of Pharmaceutical Sciences ( P-ISSN 1683 - 3597 E-ISSN 2521 - 3512).

[2]  A. Chenthilnathan,et al.  Formulation development and evaluation of taste masked Cefuroxime axetil dry suspension , 2013 .

[3]  N. G. R. Rao,et al.  Overview on Controlled Release Dosage Form , 2013 .

[4]  S. Bhaskaran,et al.  Dry Suspension Formulation of Taste Masked Antibiotic Drug for Pediatric Use , 2012 .

[5]  A. Bozkır,et al.  Formulation and evaluation of reconstitutable suspensions containing ibuprofen-loaded Eudragit microspheres. , 2011, Acta poloniae pharmaceutica.

[6]  雷蒙·帕森斯 Use PTEN-Long leader sequence transmembrane delivery of molecules , 2011 .

[7]  R. Doijad,et al.  An Approch For Development Of Oral Sustained Release Suspension , 2011 .

[8]  라지브 고칼레,et al.  Stable nanoparticulate drug suspension , 2010 .

[9]  Asgar Ali,et al.  FORMULATION AND IN VITRO EVALUATION OF READYUSE SUSPENSION OF AMPIILLIN TRIHYDRATE , 2010 .

[10]  R. Mutahar,et al.  Formulation and stability study of palatable norfloxacin dry syrup: comparison among different preparation methods , 2010 .

[11]  拉米雷斯 莫内塔 罗德里格·伊凡 Immunosuppressive macrolide powder for oral suspension , 2009 .

[12]  マーフィー,エドウィン・カレン,et al.  Injectable meclizine formulations and methods , 2008 .

[13]  배어 한스,et al.  Ph-dependent controlled release pharmaceutical opioid composition with resistance against the influence of ethanol , 2008 .

[14]  J. Emami,et al.  Preparation and evaluation of a liquid sustained-release drug delivery system for theophylline using spray-drying technique , 2008 .

[15]  T. Mickle POLAR HYDROPHILIC PRODRUGS OF AMPHETAMINE AND OTHER STIMULANTS AND PROCESSES FOR MAKING AND USING THE SAME RELATED APPLICATIONS , 2008 .

[16]  F. Guimberteau,et al.  microparticulate oral pharmaceutical form anti-misuse , 2005 .

[17]  D·B·赫克,et al.  Sulfoalkyl ether cyclodextrin compositions and methods for preparing , 2005 .

[18]  P. Linko,et al.  Microencapsulation of l-menthol by spray drying and its release characteristics , 2005 .

[19]  아테프 에이. 가예드,et al.  Taste-masked formulations containing sertraline and sulfoalkyl ether cyclodextrin , 2005 .

[20]  모쉐 게롤드엘.,et al.  Inhalant formulation containing sulfoalkyl ether cyclodextrin and corticosteroid prepared from a unit dose suspension , 2004 .

[21]  Яков Яковлевич Махмудов,et al.  Method for treating chronic abacterial prostatitis/syndrome of chronic noninflammatory pelvic pain , 2003 .

[22]  F. Guimberteau,et al.  oral pharmaceutical formulation in the form of aqueous suspension of microcapsules for modified release principle (s) active (s) , 2002 .

[23]  E. Doelker,et al.  Biopharmaceutical comparison of oral multiple-unit and single-unit sustained-release dosage forms , 1992 .